Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
1 report, 1 independent
Updated Aug 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Barclays
British bank
-
BioMarin Pharmaceutical
American company
Nothing else this week.
Related events
- Multiple financial firms (Barclays, UBS, Morgan Stanley, Jefferies) issued rating and price target updates for Equity Lifestyle Properties.
- BioMarin Pharmaceutical and XTL Biopharmaceuticals are identified as healthcare companies competing for investment.
- Barclays, Citigroup, and Raymond James Financial issued rating updates for Alaska Airlines Group on October 23, 2026.
Coverage
Newest first; wire copies grouped- Insider MonkeyBarclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks according to Wall Street anal